BioXcel Therapeutics, Inc.
General ticker "BTAI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $26.1M (TTM average)
BioXcel Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -28.2%.
Estimated limits based on current volatility of 3.0%: low 0.78$, high 0.82$
Factors to consider:
- Earnings expected soon, date: 2026-08-11 bmo
- Total employees count: 29 (-21.6%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Manufacturing risks, Market competition
- Current price 42.4% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.40$, 5.01$]
- 2026-12-31 to 2027-12-31 estimated range: [0.95$, 3.56$]
Financial Metrics affecting the BTAI estimates:
- Positive: with PPE of -0.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -286.52 <= 0.30
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of -212.54 <= 19.10
Short-term BTAI quotes
Long-term BTAI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.38MM | $2.27MM | $0.64MM |
| Operating Expenses | $173.16MM | $69.51MM | $51.10MM |
| Operating Income | $-171.78MM | $-67.25MM | $-50.46MM |
| Non-Operating Income | $-7.27MM | $7.65MM | $-19.44MM |
| Interest Expense | $13.31MM | $15.13MM | $16.98MM |
| R&D Expense | $84.33MM | $30.43MM | $30.25MM |
| Income(Loss) | $-179.05MM | $-59.60MM | $-69.90MM |
| Net Income(Loss)* | $-179.05MM | $-59.60MM | $-69.90MM |
| Stockholders Equity | $-56.51MM | $-93.10MM | $-95.46MM |
| Inventory | $1.99MM | $0.68MM | $0.72MM |
| Assets | $73.70MM | $38.34MM | $44.92MM |
| Operating Cash Flow | $-155.01MM | $-72.03MM | $-57.62MM |
| Capital expenditure | $0.02MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.02MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $26.52MM | $36.66MM | $56.52MM |
| Earnings Per Share** | $-98.35 | $-23.51 | $-5.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.